N/A
N=144
Mindfulness During COVID-19
Migraine Disorders · Stress · Anxiety
Bottom Line
View on ClinicalTrials.gov: NCT04319445 ↗Enrolled (actual)
144
Serious AEs
0.0%
Results posted
Mar 2022
Primary outcome: Primary: Helpfulness of the Session — 89 percentage of participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Mindfulness session(s) (Behavioral)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- Wake Forest University Health Sciences
- Primary completion
- Jul 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Helpfulness of the Session |
89 | — |
| PRIMARY Platform Effectiveness |
89 | — |
| SECONDARY Change in Anxiety Level |
76 | — |
| SECONDARY Change in Stress Level |
80 | — |
| SECONDARY Value of the Session |
87 | — |
| SECONDARY Satisfaction With the Session |
92 | — |
| SECONDARY Percentage of Participants That Showed Interest in a Future Session |
131 | — |
| SECONDARY Percentage of Participants That Would Recommend This Session to a Family Member |
137 | — |
| SECONDARY Percentage of Participants by Session Frequency Preference - Daily |
51 | — |
| SECONDARY Percentage of Participants by Session Frequency Preference - Weekly |
69 | — |
| SECONDARY Percentage of Participants by Session Frequency Preference - Monthly |
24 | — |
Summary
The objective of this study is to provide remote mindfulness session(s) to help during the COVID-19 pandemic.
Eligibility Criteria
Inclusion Criteria
- Any person interested in participating in the mindfulness session will be eligible to complete the pre/post surveys and participate in the mindfulness session.
Exclusion Criteria
- None
Data sourced from ClinicalTrials.gov (NCT04319445). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.